With the deepening of research, DNA mismatch repair-deficient/microsatellite instability (dMMR/MSI) (66), tumor mutational burden (TMB) (67), copy number variation (CNV), polymerase epsilon (POLE) (68, 69), circulating tumor DNA (ctDNA) (70), inflamed gene expression profile (71, 72), tumor-infiltrating lymphocytes (TILs) (73), and immune gene signatures (74) have been suggested to show certain potential in predicting efficacy, which deserve further verification. Here, POLE is linked to neoplasm.